Centene reported third quarter adjusted diluted earnings per share of $0.58, ahead of expectations, and raised its 2026 outlook to greater than $5.20 per diluted share from greater than $4.80, supported by Medicare strength and Marketplace margin improvement.
CNC · Centene Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Centene Corporation reported third-quarter 2026 GAAP loss per share of $(0.14), adjusted diluted EPS of $0.58 and HBR of 92.7%. It raised 2026 GAAP diluted EPS guidance to greater than $3.46 and adjusted diluted EPS guidance to greater than $5.20.
Centene reported third-quarter 2026 revenue growth of 2%, while membership fell 2.3 million, operating cash flows used $3.7 billion, GAAP diluted loss per share was $(0.14), and adjusted diluted EPS was $0.58.
Centene Corporation delivered notice on October 8, 2026 to redeem all $568,664,000 principal amount of its 4.25% Notes due December 15, 2027 on October 23, 2026, at 100% plus accrued interest, leaving no such notes outstanding.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 27, 2026TL;DR. Centene reported better-than-expected Q3 adjusted diluted EPS of $0.58, raised 2026 adjusted EPS guidance to greater than $5.20 from greater than $4.80, improved its full-year HBR outlook, reduced debt, and expects adjusted EPS to grow in 2027. Risks include Medicaid membership attrition and rate-acuity pressure, Marketplace membership attrition, lower Medicare Advantage membership, a PDP margin reset, and enterprise optimization costs.
- + The full-year 2026 HBR midpoint improved by 15 basis points to 90.75%. new
- + Marketplace is expected to deliver a full-year pre-tax margin at the top of its previous 4.5% to 5% range. new
- + Debt fell by $1.1 billion since June 30, 2026, including full redemption of the 2027 Senior Notes in October. new
- − Medicaid membership is expected to decline 8% to 9% in 2026, with a larger Q4 step-down and associated acuity pressure. new
- − Q3 produced a GAAP diluted loss per share of $(0.14). new
- − Enterprise optimization produced $276 million of severance costs and $35 million of third-party vendor costs in Q3. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted EPS non-GAAP | $2.51 | second quarter of 2026 filing | — |
| Adjusted SG&A expense ratio non-GAAP | 6.9% | second quarter of 2026 filing | — |
| Cost of service ratio | 91.9% | the three months ended June 30, 2026 filing | — |
| Effective tax rate on adjusted earnings non-GAAP | 26.5% | the second quarter of 2026 filing | — |
| HBR | 89.6% | the three months ended June 30, 2026 filing | — |
| Managed care membership | 25.9M | second quarter of 2026 filing | — |
| Operating cash flows | 3.6B | second quarter of 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNC
this stock
Centene Corp
|
$37.02B | +81.7% | +19.4% | 24.8 | 2.1% |
|
UNH
Unitedhealth Group Inc
|
$369.18B | +24.8% | +11.8% | 23.5 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$113.35B | +11.6% | +7.8% | 10.3 | 1.4% |
|
ELV
Elevance Health, Inc.
|
$96.42B | +27.3% | +12.5% | 19.0 | 2.1% |
|
CI
Cigna Group
|
$79.09B | +9.1% | +11.2% | 13.3 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 27, 2026
- This year
- 20
Centene Corporation reported third-quarter 2026 GAAP loss per share of $(0.14), adjusted diluted EPS of $0.58 and HBR of 92.7%. It raised 2026 GAAP diluted EPS guidance to greater than $3.46 and adjusted diluted EPS guidance to greater than $5.20.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNC | +9.1% | +9.0% | +27.1% | +9.2% | +81.7% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | +10.8% | +12.4% | +28.5% | +11.3% | +73.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.